Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GH Guardant Health Inc.

已收盘 08-14 16:00:00 EDT

157.21

-2.33

-1.46%

盘后156.80

-0.41-0.26%

19:58 EDT

最高159.71	最低156.21	成交量256.48万
今开157.93	昨收159.54	日振幅2.19%
总市值210.97亿	流通市值204.02亿	总股本1.34亿
成交额4.03亿	换手率1.98%	流通股本1.30亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":157.21,"timestamp":1786737600000,"preClose":159.54,"halted":0,"volume":2564787,"hourTrading":{"tag":"盘后","latestPrice":156.8,"preClose":157.21,"latestTime":"19:58 EDT","volume":98690,"amount":15514913.6925,"timestamp":1786751899345,"change":-0.41,"changeRate":-0.002608,"amplitude":0.004285},"delay":0,"changeRate":-0.014604487902720223,"floatShares":129778058,"shares":134196170,"eps":-3.503749,"marketStatus":"已收盘","change":-2.33,"latestTime":"08-14 16:00:00 EDT","open":157.93,"high":159.71,"low":156.21,"amount":402648655.45209,"amplitude":0.021938,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.503749,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":159.54,"preHourTrading":{"tag":"盘前","latestPrice":157.8,"preClose":159.54,"latestTime":"09:25 EDT","volume":1050,"amount":166064.22,"timestamp":1786713900012,"change":-1.74,"changeRate":-0.010906,"amplitude":0.022157},"postHourTrading":{"tag":"盘后","latestPrice":156.8,"preClose":157.21,"latestTime":"19:58 EDT","volume":98690,"amount":15514913.6925,"timestamp":1786751899345,"change":-0.41,"changeRate":-0.002608,"amplitude":0.004285},"volumeRatio":1.418109,"impliedVol":0.4116,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"1122159182","title":"异动解读｜Guardant Health盘中上涨5.39%，Q2营收大超预期叠加全年指引上调延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1122159182","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122159182?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:56","pubTimestamp":1786111001,"startTime":"0","endTime":"0","summary":"8月7日，Guardant Health盘中上涨5.39%，报166.35美元/股，成交额4265.67万美元，延续财报发布后的上行势头。消息面上，公司此前公布的Q2财报显示营收3.35亿美元，同比增长44.3%，大幅超出市场预期的3.14亿美元；同时将全年营收指引从13.0亿-13.2亿美元上调至13.4亿-13.6亿美元，显著高于分析师预期的13.1亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Guardant Health盘中上涨5.39%，Q2营收大超预期叠加全年指引上调延续强势","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183698521","title":"异动解读｜Guardant Health夜盘上涨5.67%，Q2营收大超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1183698521","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183698521?lang=zh_cn&edition=full","pubTime":"2026-07-31 11:38","pubTimestamp":1785469114,"startTime":"0","endTime":"0","summary":"7月31日，Guardant Health夜盘上涨5.67%，报160.99美元/股。消息面上，公司盘后发布第二季度财报，营收达3.35亿美元，同比增长44.3%，显著超出市场预期的3.14亿美元；调整后每股亏损0.42美元，同比收窄。此外，近期公司获得多项积极进展，包括Guardant360 Liquid CDx获FDA批准为多癌种伴随诊断、Shield血检被纳入美国癌症学会结直肠癌筛查指南，以及多家机构上调目标价，共同提振市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Guardant Health夜盘上涨5.67%，Q2营收大超预期且上调全年指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171842386","title":"异动解读 | 夜盘大涨5.67%，Guardant Health Q2财报超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1171842386","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171842386?lang=zh_cn&edition=full","pubTime":"2026-07-31 11:28","pubTimestamp":1785468536,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.今日夜盘股价大涨5.67%，引起了市场的广泛关注。消息面上，公司于盘后发布了第二季度财报，营收达3.35亿美元，同比增长44.3%，显著超出市场预期的3.14亿美元；调整后每股亏损0.42美元，同比大幅收窄。强劲的业绩表现和乐观的指引是推动夜盘股价大涨的核心原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180776923","title":"异动解读｜Guardant Health盘后上涨6.33%，Q2营收大超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1180776923","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180776923?lang=zh_cn&edition=full","pubTime":"2026-07-31 05:56","pubTimestamp":1785448597,"startTime":"0","endTime":"0","summary":"7月31日，Guardant Health盘后上涨6.33%，报163.3美元/股，成交额3296.06万美元。消息面上，公司发布Q2财报，营收3.35亿美元，同比增长44.3%，超出市场预期的3.14亿美元；调整后每股亏损0.42美元，同比收窄。营收大幅超预期叠加指引上调，推动盘后股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169449015","title":"异动解读 | Guardant Health盘后大涨7.65%，Q2财报超预期叠加多重利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1169449015","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169449015?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:48","pubTimestamp":1785444536,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.今日盘后股价大涨7.65%，引发市场高度关注。作为肿瘤精准诊断龙头企业，Guardant Health的伴随诊断产品直接受益于抗癌药物使用量的增长。近期，Guardant Health还获得了一系列积极进展，包括Guardant360 Liquid CDx获得FDA批准、Shield血检被纳入美国癌症学会指南，以及多家机构上调目标价等，这些因素共同提振了市场情绪，为股价盘后大涨提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125499334","title":"异动解读｜Guardant Health盘中上涨5.02%，百时美施贵宝抗癌药业绩超预期提振肿瘤诊断板块","url":"https://stock-news.laohu8.com/highlight/detail?id=1125499334","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125499334?lang=zh_cn&edition=full","pubTime":"2026-07-31 00:15","pubTimestamp":1785428142,"startTime":"0","endTime":"0","summary":"7月30日，Guardant Health盘中上涨5.02%，报151.295美元/股，成交额1.75亿美元。消息面上，百时美施贵宝同日公布Q2财报，旗下癌症药物需求全面超预期，季度营收129.7亿美元超市场预期逾10亿美元，并大幅上调全年指引。作为肿瘤精准诊断龙头，Guardant Health的伴随诊断产品直接受益于抗癌药物使用增长。此外，公司将于当日盘后发布Q2财报，市场预期营收3.14亿美元，叠加近期Guardant360 Liquid CDx获FDA批准、Shield血检纳入美国癌症学会指南及多家机构上调目标价等利好，市场情绪偏乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148213813","title":"财报前瞻 ｜Guardant Health Inc.本季度营收预计增长48.77%，机构看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1148213813","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148213813?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:38","pubTimestamp":1784777894,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.将于2026年07月30日美股盘后发布财报，市场关注收入延续高增与亏损收窄的节奏。一致预期显示，本季度公司收入预计为3.14亿美元，同比增长48.77%；调整后每股收益预计为-0.41美元，同比改善47.05%；由于未检索到覆盖本季度的公司层面毛利率与净利润或净利率的明确口径，上述两项预测不予展示。上季度财报未给出针对本季度的明确分项指引，市场以机构一致预期为主要参考。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Guardant Health Inc.本季度营收预计增长48.77%，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174386951","title":"异动解读｜Guardant Health盘中下跌5.06%，报147.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174386951","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174386951?lang=zh_cn&edition=full","pubTime":"2026-07-20 23:03","pubTimestamp":1784559813,"startTime":"0","endTime":"0","summary":"7月17日，Guardant Health盘中下跌5.06%，报147.99美元/股，成交额7437.5万美元。Guardant Health所在的保健护理服务行业中，个股中，BrightSpring Health Services涨1.89%，信诺保险涨1.01%，Hims & Hers Health涨0.52%，西维斯健康跌0.01%，BillionToOne跌4.8%。Guardant Health是一家领先的精密肿瘤学公司，利用先进的血液和组织检测、真实世界数据和人工智能分析，提供关于疾病驱动因素的关键见解，其检测覆盖早期癌症筛查、复发监测及晚期治疗方案选择等多个阶段。公司下次财报预计于7月30日盘后发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126421777","title":"异动解读｜Guardant Health盘中下跌5.02%，报154.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126421777","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126421777?lang=zh_cn&edition=full","pubTime":"2026-07-17 03:59","pubTimestamp":1784231981,"startTime":"0","endTime":"0","summary":"7月17日，Guardant Health盘中下跌5.02%，报154.81美元/股，成交额3.46亿美元。Guardant Health所在的保健护理服务行业中，个股中，奎斯特诊疗涨3.72%，西维斯健康涨0.53%，BrightSpring Health Services跌0.04%，信诺保险跌4.86%，Hims & Hers Health跌9.46%。Guardant Health是一家领先的精密肿瘤学公司，利用先进的血液和组织检测、真实世界数据和人工智能分析，提供关于疾病驱动因素的关键见解，其检测覆盖早期癌症筛查、复发监测及晚期治疗方案选择等多个阶段。公司下次财报预计于7月30日盘后发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129946907","title":"异动解读｜Guardant Health盘中上涨5.21%，美银大幅上调目标价至190美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129946907","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129946907?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:14","pubTimestamp":1783606452,"startTime":"0","endTime":"0","summary":"7月9日，Guardant Health盘中上涨5.21%，报168.5美元/股，成交额1.28亿美元。消息面上，美银证券近日将Guardant Health目标价从135美元大幅上调至190美元，维持买入评级。近期公司连续获得多项FDA批准，包括Guardant360 Liquid CDx获批用于非小细胞肺癌及结直肠癌伴随诊断，Shield血液检测纳入美国癌症协会结直肠癌筛查指南，叠加一季度营收3.02亿美元超预期、全年收入指引上调至13.0亿至13.2亿美元，多重利好持续推动市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125693974","title":"异动解读｜Guardant Health盘中上涨7.47%，伯恩斯坦看好ADLT定价资格带来营收上行空间","url":"https://stock-news.laohu8.com/highlight/detail?id=1125693974","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125693974?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:01","pubTimestamp":1782914487,"startTime":"0","endTime":"0","summary":"7月1日，Guardant Health盘中上涨7.47%，报161.78美元/股，成交额1.96亿美元。消息面上，伯恩斯坦发布最新研报，给予公司\"跑赢大市\"评级及175美元目标价，指出G360 ADLT定价资格将带来可观营收上行空间，且尚未充分反映在市场一致预期中。叠加近期Guardant360 Liquid CDx获FDA批准及Shield血液检测纳入美国癌症协会筛查指南等多重催化，市场情绪持续升温。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169680987","title":"异动解读｜Guardant Health盘前上涨5.35%，伯恩斯坦看好ADLT定价资格带来营收上行空间","url":"https://stock-news.laohu8.com/highlight/detail?id=1169680987","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169680987?lang=zh_cn&edition=full","pubTime":"2026-07-01 21:23","pubTimestamp":1782912206,"startTime":"0","endTime":"0","summary":"7月1日，Guardant Health盘前上涨5.35%，报158.05美元/股，成交额67.2万美元。消息面上，伯恩斯坦在最新研报中给予该公司\"跑赢大市\"评级及175美元目标价，指出G360 ADLT定价资格将带来可观营收上行空间，且尚未充分反映在市场一致预期中。伯恩斯坦对公司2027年盈利预测较一致预期高6.6%，2028年高12.2%，并认为市场明显低估其毛利率改善潜力，向NovaSeq X平台切换预计为全年带来350至550个基点的正面影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115063321","title":"异动解读｜Guardant Health盘中上涨5.08%，多重利好催化延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1115063321","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115063321?lang=zh_cn&edition=full","pubTime":"2026-06-27 00:36","pubTimestamp":1782491812,"startTime":"0","endTime":"0","summary":"6月27日，Guardant Health盘中上涨5.08%，报150.2美元/股，成交额1.77亿美元。近期多重利好共振持续推动股价走强。消息面上，RBC Capital Markets于6月12日首次覆盖并给予\"跑赢大盘\"评级及185美元目标价，指出美国仅约25%的转移性癌症患者接受基因组分析，公司作为市场领导者最受益于行业渗透扩大。此外，Guardant360 CDx于6月11日获FDA批准作为非小细胞肺癌伴随诊断，叠加一季度业绩大超预期及全年收入指引上调至13.0亿-13.2亿美元，多重催化共振推动股价连续走高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180460572","title":"异动解读｜Guardant Health盘中上涨5.05%，多重利好催化延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1180460572","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180460572?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:31","pubTimestamp":1782397862,"startTime":"0","endTime":"0","summary":"6月25日，Guardant Health盘中上涨5.05%，报143.31美元/股，成交额7875.13万美元。消息面上，RBC Capital Markets于6月12日首次覆盖并给予\"跑赢大盘\"评级及185美元目标价，指出美国仅约25%的转移性癌症患者接受基因组分析，公司作为市场领导者最受益于行业渗透扩大。此外，6月11日Guardant360 CDx获FDA批准作为非小细胞肺癌伴随诊断，叠加一季度业绩大超预期及全年收入指引上调至13.0亿-13.2亿美元，多重催化共振推动股价延续强势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123755623","title":"异动解读｜Guardant Health盘中上涨5.22%，报137.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123755623","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123755623?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:35","pubTimestamp":1782311704,"startTime":"0","endTime":"0","summary":"6月24日，Guardant Health盘中上涨5.22%，报137.51美元/股，成交额9828.98万美元。Guardant Health所在的保健护理服务行业中，个股中，BillionToOne涨4.97%，奎斯特诊疗涨2.15%，西维斯健康跌1.45%，Hims & Hers Health跌1.93%，信诺保险跌2.68%。Guardant Health是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试、大量数据集和高级分析来帮助全球征服癌症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173869903","title":"Guardant Health宣布Guardant360 Cdx获FDA批准，作为勃林格殷格翰Hernexeos®的伴随诊断","url":"https://stock-news.laohu8.com/highlight/detail?id=1173869903","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173869903?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:07","pubTimestamp":1781179639,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. 宣布，其Guardant360 Cdx检测产品已获得美国食品药品监督管理局的批准，将作为勃林格殷格翰公司靶向药物Hernexeos的伴随诊断使用。此次批准意味着，临床医生现在可以使用Guardant Health的液体活检技术，通过简单的血液检测来确定患者是否适合接受Hernexeos治疗。对于Guardant Health而言，此次FDA批准是其产品商业化进程中的一个重要里程碑，有望进一步巩固其在液体活检和伴随诊断市场的地位。Hernexeos是勃林格殷格翰开发的一款针对特定基因突变的新型抗癌药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","BK4585","BK4551","GH","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171389861","title":"Evercore ISI将Guardant Health评级从“符合预期”上调至“跑赢大盘”，目标价大幅提升至160美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171389861","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171389861?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:05","pubTimestamp":1780394728,"startTime":"0","endTime":"0","summary":"Evercore ISI的分析师将Guardant Health Inc.的股票评级从“符合预期”上调至“跑赢大盘”，同时将其目标价从95美元大幅调升至160美元。此举反映了该机构对该公司前景的显著看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4551","BK4585","BK4196","GH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184911159","title":"异动解读｜Guardant Health盘前上涨5.87%，Shield血液测试纳入美国癌症协会筛查指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1184911159","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184911159?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:35","pubTimestamp":1779957302,"startTime":"0","endTime":"0","summary":"5月28日，Guardant Health盘前上涨5.87%，报127.78美元/股，成交额8.48万美元。消息面上，公司宣布其Shield血液测试已被纳入美国癌症协会更新的结直肠癌筛查指南，该指南建议将Shield作为拒绝或未完成粪便检测及视觉检查筛查的患者的替代选项，进一步验证了公司在液体活检领域的临床价值。此前5月21日，公司另一款Guardant360 Liquid CDx液体活检测试获美国FDA批准，作为非小细胞肺癌和结直肠癌多种疗法的伴随诊断工具，基因组覆盖范围较此前获批版本扩大100倍。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115365028","title":"异动解读｜Guardant Health盘中上涨5.26%，Shield血液测试纳入美国癌症协会筛查指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1115365028","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115365028?lang=zh_cn&edition=full","pubTime":"2026-05-28 00:47","pubTimestamp":1779900443,"startTime":"0","endTime":"0","summary":"5月28日，Guardant Health盘中上涨5.26%，报126.155美元/股，成交额1.9亿美元。消息面上，公司宣布其Shield血液测试已被纳入美国癌症协会更新的结直肠癌筛查指南。该指南建议将Shield作为拒绝或未完成粪便检测及视觉检查筛查的患者的替代选项，进一步验证了公司在液体活检领域的临床价值。Guardant Health是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试、大量数据集和高级分析来帮助全球征服癌症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158523251","title":"异动解读｜Guardant Health盘前下跌8.48%，报118.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158523251","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158523251?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:03","pubTimestamp":1779447799,"startTime":"0","endTime":"0","summary":"5月22日，Guardant Health盘前下跌8.48%，报118.01美元/股，成交额3.69万美元。Guardant Health所在的保健护理服务行业中，个股中，西维斯健康跌0.09%，Hims & Hers Health Inc.跌0.46%，信诺保险跌0.46%，达维塔保健跌0.01%，BrightSpring Health Services Inc.涨0.02%。Guardant Health是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试、大量数据集和高级分析来帮助全球征服癌症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":-0.0036},{"period":"3month","weight":0.6808},{"period":"6month","weight":0.5216},{"period":"1year","weight":1.7239},{"period":"ytd","weight":0.562}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Guardant Health, Inc.于2011年12月在特拉华州注册成立。该公司是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试，大量数据集和高级分析来帮助全球征服癌症。他们利用先进的血液和组织检测、真实世界数据和人工智能分析，提供关于疾病驱动因素的关键见解，从而变革患者护理。他们的检测有助于改善各个阶段的治疗效果，包括早期癌症筛查、早期癌症复发监测以及晚期癌症患者的治疗方案选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022808},{"month":4,"riseRate":0.375,"avgChangeRate":-0.022604},{"month":5,"riseRate":0.625,"avgChangeRate":0.118443},{"month":6,"riseRate":0.75,"avgChangeRate":0.091261},{"month":7,"riseRate":0.75,"avgChangeRate":0.055},{"month":8,"riseRate":0.5,"avgChangeRate":0.071137},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Guardant Health Inc.(GH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Guardant Health Inc.(GH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}